Heterocycle-Aware Nanocarrier Design: Linking Ionisation, Solid-State Chemistry, Loading, Release, and Translational Evidence

Mahmoud Khatib Al-Ruweidi^1,*, Rakan Al-Zu'bi³, Mohammed G. Nassr², Abdelgalil Khalaf Ahmed², Abdelrahman Adel Mahmoud²

Corresponding author: [email protected]

Abstract

Heterocyclic motifs influence pharmaceutical performance well beyond molecular recognition at the therapeutic target. Heteroatom topology, aromaticity, tautomerism, ionisation, coordination capacity and substituent pattern can alter hydration, crystal packing, membrane permeation, carrier association, chemical stability, metabolism, transporter recognition and subcellular disposition. This chapter develops a heterocycle-aware design strategy that connects those molecular properties to four product decisions: diagnosing the dominant solution- or solid-state liability; establishing whether nanoformulation is necessary; selecting an architecture and a loading–retention–release mechanism; and constructing the analytical, biological, manufacturing and translational evidence needed to support development. The heterocycle is treated as a source of experimentally testable priors rather than as a carrier-selection label, and every ring-derived inference is corrected for the complete molecular structure, solid form, dose, route, target compartment and comparator. Clinical liposomal products demonstrate that control of release, disposition or multidrug exposure ratio can improve benefit–risk in defined regimens. By contrast, ligand-targeted, coordination-based, inorganic and self-assembling systems generally require stronger evidence that the administered construct generates unbound or pharmacologically active drug at the intended site. The governing principle is parsimonious: a nanocarrier is justified only when it corrects a measured limitation more effectively than a simpler formulation and preserves that advantage through manufacture, storage, administration, biological exchange, release and target engagement.

Author Affiliations

• ¹ Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
• ² Center for Advanced Materials, Qatar University, Doha, Qatar.

How to Cite this Chapter